Freenome Q3 Earnings Call Highlights
Freenome Reports Third Quarter 2026 Financial Results
Freenome Q3 2026 Earnings Call Transcript
UPDATE: Freenome Q3 Adj. EPS $1.10 Beats $0.41 Estimate, Sales $183.489M Beat $105.866M Estimate
Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung
Freenome (FRNM) Climbed, But What Is Driving Attention Now?
Freenome shares are trading higher after the company announced FDA approval for its SimpleSreen CRC blood-based screening test.
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
Perceptive Capital Q2 EPS $(0.01) Down From $0.07 YoY
Perceptive Capital, Freenome Holdings Announce Their Form S-4 Registration Regarding Proposed Merger Declared Effective By U.S. SEC; Business Combination Expected To Be Completed In July
Perceptive Capital Q1 EPS $0.00 Down From $0.06 YoY
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.